A meta-analysis indicated that high CXCR4 expression was associated with poor prognosis in ovarian cancer [64] and CXCR4 expression was significantly reduced in vivo after treatment with R-ketorolac. This evidence concerns the gene CXCR4 and ovarian cancer.